Mesdopetam

Mesdopetam
Clinical data
Other names	IRL-790; IRL790; IPN60170
Drug class	Atypical dopamine D2 and D3 receptor antagonist
Pharmacokinetic data
Elimination half-life	7 hours
Identifiers
	IUPAC name N-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]propan-1-amine;
CAS Number	1403894-72-3;
PubChem CID	70980485;
DrugBank	DB16229;
ChemSpider	81367293;
UNII	HD4QV8GX26;
ChEMBL	ChEMBL4594447;
Chemical and physical data
Formula	C12H18FNO3S
Molar mass	275.34 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCNCCOC1=CC(=CC(=C1)S(=O)(=O)C)F;
	InChI InChI=1S/C12H18FNO3S/c1-3-4-14-5-6-17-11-7-10(13)8-12(9-11)18(2,15)16/h7-9,14H,3-6H2,1-2H3; Key:OSBPYFBXSLJHCR-UHFFFAOYSA-N;

Mesdopetam (INNTooltip International Nonproprietary Name; developmental code names IRL-790, IPN60170) is a dopamine D₂ and D₃ receptor antagonist with preference for the D₃ receptor which is under development for the treatment of Parkinson's disease, drug-induced dyskinesia, and psychotic disorders.^[2]^[3]^[4]^[5]^[6] It has been described by its developers as having "psychomotor stabilizing" properties.^[7]^[8]

^ Sjöberg F, Waters S, Löfberg B, Sonesson C, Waters N, Tedroff J (May 2021). "A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers". Pharmacol Res Perspect. 9 (3): e00792. doi:10.1002/prp2.792. PMC 8137807. PMID 34018344.
^ "Mesdopetam - Integrative Research Laboratories". AdisInsight. 6 September 2024. Retrieved 25 September 2024.
^ Alsalmi M, Al-Kassmy J, Kang W, Palayew M, Huot P (2024). "Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?". Expert Opin Pharmacother. 25 (1): 1–3. doi:10.1080/14656566.2023.2298345. PMID 38116733.
^ Kiss B, Laszlovszky I, Krámos B, Visegrády A, Bobok A, Lévay G, Lendvai B, Román V (January 2021). "Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders". Biomolecules. 11 (1): 104. doi:10.3390/biom11010104. PMC 7830622. PMID 33466844.
^ Cite error: The named reference AlShimemeriFoxVisanji2020 was invoked but never defined (see the help page).
^ Waters S, Sonesson C, Svensson P, Tedroff J, Carta M, Ljung E, Gunnergren J, Edling M, Svanberg B, Fagerberg A, Kullingsjö J, Hjorth S, Waters N (July 2020). "Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease". J Pharmacol Exp Ther. 374 (1): 113–125. doi:10.1124/jpet.119.264226. hdl:11584/423003. PMID 32358046.
^ Fabbrini A, Guerra A (2021). "Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia". J Exp Pharmacol. 13: 469–485. doi:10.2147/JEP.S265282. PMC 8092630. PMID 33953618.
^ Dragašević-Mišković N, Petrović I, Stanković I, Kostić VS (February 2019). "Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients". Expert Opin Pharmacother. 20 (2): 219–230. doi:10.1080/14656566.2018.1543407. PMID 30411647.

[SjöbergWatersLöfberg2021-1] Sjöberg F, Waters S, Löfberg B, Sonesson C, Waters N, Tedroff J (May 2021). "A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers". Pharmacol Res Perspect. 9 (3): e00792. doi:10.1002/prp2.792. PMC 8137807. PMID 34018344.

[AdisInsight-2] "Mesdopetam - Integrative Research Laboratories". AdisInsight. 6 September 2024. Retrieved 25 September 2024.

[AlsalmiAl-KassmyKang2024-3] Alsalmi M, Al-Kassmy J, Kang W, Palayew M, Huot P (2024). "Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?". Expert Opin Pharmacother. 25 (1): 1–3. doi:10.1080/14656566.2023.2298345. PMID 38116733.

[KissLaszlovszkyKrámos2021-4] Kiss B, Laszlovszky I, Krámos B, Visegrády A, Bobok A, Lévay G, Lendvai B, Román V (January 2021). "Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders". Biomolecules. 11 (1): 104. doi:10.3390/biom11010104. PMC 7830622. PMID 33466844.

[AlShimemeriFoxVisanji2020-5] Cite error: The named reference AlShimemeriFoxVisanji2020 was invoked but never defined (see the help page).

[WatersSonessonSvensson2020-6] Waters S, Sonesson C, Svensson P, Tedroff J, Carta M, Ljung E, Gunnergren J, Edling M, Svanberg B, Fagerberg A, Kullingsjö J, Hjorth S, Waters N (July 2020). "Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease". J Pharmacol Exp Ther. 374 (1): 113–125. doi:10.1124/jpet.119.264226. hdl:11584/423003. PMID 32358046.

[FabbriniGuerra2021-7] Fabbrini A, Guerra A (2021). "Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia". J Exp Pharmacol. 13: 469–485. doi:10.2147/JEP.S265282. PMC 8092630. PMID 33953618.

[Dragašević-MiškovićPetrovićStanković2019-8] Dragašević-Mišković N, Petrović I, Stanković I, Kostić VS (February 2019). "Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients". Expert Opin Pharmacother. 20 (2): 219–230. doi:10.1080/14656566.2018.1543407. PMID 30411647.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]